Principal Results of the VITamin D and OmegA-3 TriaL (VITAL) and Updated Meta-analyses of Relevant Vitamin D Trials
Descripción general
Resumen del artículo
In a large randomized trial, daily high-dose vitamin D (2000 IU) did not prevent cancer or cardiovascular disease. However, it was associated with reduced cancer mortality after excluding the first two years of follow-up. Meta-analyses including VITAL data show similar results.
Explícamelo como si tuviera cinco años
Scientists found that taking a lot of vitamin D didn't stop people from getting cancer or heart disease. But, it might have helped some people who already had cancer live longer after taking it for a while.
Posibles conflictos de intereses
Pharmavite LLC and Pronova BioPharma/BASF donated the study agents and placebos. Quest Diagnostics provided lab tests at no cost. However, the NIH sponsors played a role in the study's design and interpretation, but final decisions rested with the VITAL investigators. Authors submitted conflict of interest disclosures.
Limitaciones identificadas
Explicación de la calificación
This was a large, well-designed randomized controlled trial which addressed an important clinical question. While the primary endpoints were null for incident cancer and CVD, the signal regarding cancer mortality warrants further investigation. The transparency about limitations and funding sources strengthens the study's credibility.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →